Compass Pathways falls after depression drug study data disappoints Wall Street

COMPASS Pathways

23/06/2025 13:40

** Shares of drug developer Compass Pathways CMPS.O fall 35.4% to $2.99 premarket

** Co says its experimental psilocybin-based therapy helped significantly reduce the symptoms of difficult-to-treat depression in a late-stage study

** This was measured on a standardized depression scale after six weeks of treatment where the drug reduced depression by 3.6 points compared to a placebo

** However, investors were expecting a five point difference, brokerage RBC Capital Markets said in May

** Up to last close, stock had risen 22.5% YTD

 (Reporting by Puyaan Singh)

 ((Puyaan.Singh@thomsonreuters.com;))